APA (7th ed.) Citation

Rodríguez-Saldaña, J., Padilla-Padilla, F., Cardona-Muñoz, E. G., Romero-Antonio, Y., Arguedas-Núñez, M. M., Sander-Padilla, J. G., . . . González-Canudas, J. (2022). Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients. Cardiology Research & Practice, 1. https://doi.org/10.1155/2022/9464733

Chicago Style (17th ed.) Citation

Rodríguez-Saldaña, Joel, et al. "Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients." Cardiology Research & Practice 2022: 1. https://doi.org/10.1155/2022/9464733.

MLA (9th ed.) Citation

Rodríguez-Saldaña, Joel, et al. "Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients." Cardiology Research & Practice, 2022, p. 1, https://doi.org/10.1155/2022/9464733.